Free Trial

Wedbush's Rating of Maze Therapeutics on 9/23/2026

On September 23, 2026, Wedbush updated its outlook on Maze Therapeutics (NASDAQ:MAZE) with the action "Reiterated Rating", keeping a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Wedbush

DateCompanyAction
10/14/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Reiterated Rating
10/14/2026
AppLovin Corporation stock logo
APP
AppLovin
Lower Price Target
10/14/2026
Unity Software Inc. stock logo
U
Unity Software
Boost Price Target
10/14/2026
IMAX Corporation stock logo
IMAX
IMAX
Boost Price Target
10/13/2026
CareTrust REIT, Inc. stock logo
CTRE
CareTrust REIT
Set Price Target
10/13/2026
IonQ, Inc. stock logo
IONQ
IonQ
Reiterated Rating
More Ratings From Wedbush